Literature DB >> 21973016

Successful prophylactic use of recombinant activated factor VII (rFVIIa) in a patient with congenital FVII deficiency and inhibitors to FVII.

H Tokgoz, U Caliskan, G Lavigne-Lissalde, M Giansily-Blaizot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21973016     DOI： 10.1111/j.1365-2516.2011.02666.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  3 in total

1.  Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER).

Authors:  Mariasanta Napolitano; Muriel Giansily-Blaizot; Alberto Dolce; Jean F Schved; Guenter Auerswald; Jørgen Ingerslev; Jens Bjerre; Carmen Altisent; Pimlak Charoenkwan; Lisa Michaels; Ampaiwan Chuansumrit; Giovanni Di Minno; Umran Caliskan; Guglielmo Mariani
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

2.  Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII.

Authors:  Oscar A Marcos-Contreras; Shannon M Smith; Dwight A Bellinger; Robin A Raymer; Elizabeth Merricks; Armida Faella; Giulia Pavani; Shangzhen Zhou; Timothy C Nichols; Katherine A High; Paris Margaritis
Journal:  Blood       Date:  2015-12-23       Impact factor: 22.113

3.  Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®)).

Authors:  Nicole S Bartosh; Tara Tomlin; Christian Cable; Kathleen Halka
Journal:  Clin Pharmacol       Date:  2013-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.